Cargando…

Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients

Relevant meta-analyses have confirmed the cardiovascular and renal benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1RA) among patients with type 2 diabetes (T2D) and/or cardiorenal disease. However, it is not established whether the co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Lixin, Qin, Jiao, Wang, Dengchuan, Zhao, Yunhui, Xu, Ning, Wu, Chaowen, Yuan, Jianpeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Physiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676496/ https://www.ncbi.nlm.nih.gov/pubmed/36419835 http://dx.doi.org/10.3389/fphys.2022.1028486

Ejemplares similares

Commentary: SGLT2is vs. GLP1RAs reduce cardiovascular and all-cause mortality
por: Du, Lixin, et al.
Publicado: (2022)

Substantially different findings concerning the cardiovascular and cerebrovascular effectiveness of GLP1RAs vs. SGLT2is
por: Du, Lixin, et al.
Publicado: (2022)

Effectiveness of SGLT2is vs. GLP-1RAs on cardiovascular and cerebrovascular outcomes in T2D patients according to CVD status
por: Du, Lixin, et al.
Publicado: (2022)

Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials: Perspective on GLP-1 RA and SGLT-2i therapies
por: Ludwig, Lisa, et al.
Publicado: (2020)

FRAILTY AND THE COMPARATIVE EFFECTIVENESS AND SAFETY OF SGLT2I AND GLP1-RA IN OLDER ADULTS WITH TYPE 2 DIABETES
por: Patorno, Elisabetta, et al.
Publicado: (2019)

Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies
por: Li, Junfeng, et al.
Publicado: (2017)

Evaluation of Out-of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes and Cardiovascular Disease
por: Luo, Jing, et al.
Publicado: (2023)

SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence
por: D'Marco, Luis, et al.
Publicado: (2021)

Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction
por: Trombara, Filippo, et al.
Publicado: (2023)

FRI648 GLP-1RA And SGLT2i Treatments May Show Improved Depression Metrics In Diabetes Treatment
por: Jain, Arad, et al.
Publicado: (2023)

Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study
por: Knudsen, Jakob S., et al.
Publicado: (2020)

Monitoring the Comparative Safety of SGLT2i vs GLP-1 RA in Older Adults With Type 2 Diabetes by Frailty Status
por: Kutz, Alexander, et al.
Publicado: (2021)

SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study
por: Anson, Matthew, et al.
Publicado: (2023)

Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis
por: Morton, Jedidiah I., et al.
Publicado: (2022)

Health care utilization and costs associated with switching from DPP-4i to GLP-1RA or SGLT2i: an observational cohort study
por: Newman, Terri Victoria, et al.
Publicado: (2021)

Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages
por: Koike, Masao, et al.
Publicado: (2021)

Underprescription of SGLT2i and GLP-1 RA: CAREPRO-T2D (Cardiorenal Protection in Type 2 Diabetes) Cross-Sectional Study
por: Simões de Carvalho, Francisco, et al.
Publicado: (2023)

Treatment of HFpEF beyond the SGLT2-Is: Does the Addition of GLP-1 RA Improve Cardiometabolic Risk and Outcomes in Diabetic Patients?
por: Belli, Martina, et al.
Publicado: (2022)

SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
por: Qiu, Mei, et al.
Publicado: (2021)

Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
por: Schernthaner, Guntram, et al.
Publicado: (2020)

Optimal Glycemic Control in a Patient With HNF1A MODY With GLP-1 RA Monotherapy: Implications for Future Therapy
por: Fantasia, Kathryn L, et al.
Publicado: (2019)

Cardiovascular and cerebrovascular responses to urodynamics testing after spinal cord injury: The influence of autonomic injury
por: Sahota, Inderjeet S., et al.
Publicado: (2022)

Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
por: Longato, Enrico, et al.
Publicado: (2020)

The effect of SGLT-2 inhibitors on cardiorespiratory fitness capacity: A systematic review and meta-analysis
por: Peng, Yong, et al.
Publicado: (2023)

Cerebrovascular Dysfunction in Atrial Fibrillation
por: Junejo, Rehan T., et al.
Publicado: (2020)

MON-130 Optimal Glycemic Control in a Patient with HNF1A MODY with GLP1-RA Monotherapy: Implications for Future Therapy
por: Fantasia, Kathryn, et al.
Publicado: (2019)

Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014–2022)
por: Lin, Jialing, et al.
Publicado: (2023)

Impaired Cerebrovascular Reactivity in Huntington’s Disease
por: Chan, Suk Tak, et al.
Publicado: (2021)

SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists
por: Abdelgadir, Elamin, et al.
Publicado: (2018)

Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials
por: Gan, Sushrima, et al.
Publicado: (2020)

Cerebrovascular Compliance Within the Rigid Confines of the Skull
por: Zamir, Mair, et al.
Publicado: (2018)

The Reproducibility of Cerebrovascular Reactivity Across MRI Scanners
por: Sobczyk, Olivia, et al.
Publicado: (2021)

Measuring Cerebrovascular Reactivity: Sixteen Avoidable Pitfalls
por: Sobczyk, Olivia, et al.
Publicado: (2021)

GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway
por: Xiang, Jie, et al.
Publicado: (2023)

Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results: can definition of established cardiovascular disease be the missing link?
por: Melo, Miguel, et al.
Publicado: (2021)

Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Computational Modelling of Glucose Uptake by SGLT1 and Apical GLUT2 in the Enterocyte
por: Afshar, Nima, et al.
Publicado: (2021)

Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction
por: Gonzalez, Jimmy, et al.
Publicado: (2023)

Cerebrovascular Reactivity Assays Collateral Function in Carotid Stenosis
por: Sobczyk, Olivia, et al.
Publicado: (2020)

Editorial: Imaging Cerebrovascular Reactivity: Physiology, Physics and Therapy
por: Duffin, James, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bakuolt54uh8trp9e56n74049p